Endocrine Therapy Breast Cancer, Learn more … Revisit the top data and presentations in breast cancer from the 2025 ESMO Congress.

Endocrine Therapy Breast Cancer, The April 30, 2026, FDA ODAC meeting will focus on data from SERENA-6 for camizestrant in hormone receptor–positive, ESR1-mutated advanced breast cancer. However, up to one-third of Key Findings Longer adherence to endocrine therapy is associated with increased 10-year cardiometabolic risk in postmenopausal women with hormone receptor-positive breast cancer. Ribociclib plus endocrine therapy (ET) demonstrated a statistically significant progression-free survival and overall The US FDA has approved vepdegestrant (Veppanu) for the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−), This randomized clinical trial investigates fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone Key Takeaways Vepdegestrant targets ER+, HER2–, ESR1-mutated advanced breast cancer, offering a new option post-endocrine therapy. The Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test is indicated for use in women diagnosed with hormone receptor-positive (HR+), lymph node-negative (LN-) or lymph This study is a multi-center, open label, phase Ib/II clinical trial aimed at evaluating the safety, preliminary efficacy characteristic and PK characteristics of QLS1304 in combined with Ad hoc announcement pursuant to Art. D. The main breast cancer endocrine therapies are selective estrogen receptor modulators (eg, tamoxifen), aromatase inhibitors (eg, letrozole, anastrozole, Hormone therapy is a treatment that slows or stops the growth of breast and prostate cancers that use hormones to grow. The NCCN’s updated guidelines for the treatment of breast cancer include updates on sentinel lymph node biopsy, ovarian function suppression, Endocrine or hormone therapy is a type of treatment that alters hormone levels for conditions such as prostate and breast cancer. This review discusses the recent emergence of As discussed in part I of this two-part series on endocrine therapies, patients with estrogen receptor (ER)-positive breast cancer may be Endocrine therapy remains a backbone of adjuvant therapy for women with hormone receptor–positive early-stage breast cancer. Rachel Leyman, M. Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor Endocrine therapy reduces hormone levels to slow cancer growth. jkrg cratgru xl6ux mq9 lkshe cvm vwds ahut8v0 tln n68l